Skip to main content
. 2019 May 29;11(6):752. doi: 10.3390/cancers11060752

Figure 1.

Figure 1

(A) Plasma concentrations of paclitaxel (PTX) and everolimus (EVER) after single intravenous administration of dual-targeted PTX+EVER-loaded nanoparticles (Dual-NPs) or free PTX+EVER combination to healthy BALB/c female mice at a PTX-equivalent dose of 15 mg/kg and EVER-equivalent dose of 7.5 mg/kg. (B) EVER:PTX molar ratio of drugs released from Dual-NPs in the plasma. (n = 5).